MedTrace Logo

A Study to Determine the Safety and Efficacy of NT-501 With MHFM

NCT06397131 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-07-10

No results posted yet for this study

Summary

This study is to determine the long-term levels of CNTF, and the clinical safety and efficacy of the NT-501 implants with the Medica Hollow Fiber Membrane (MHFM) in participants with macular telangiectasia type 2.

Conditions

  • Macular Telangiectasia Type 2

Interventions

COMBINATION_PRODUCT

NT-501 CNTF Implant

Single implantation of CNTF-secreting NT-501 hCNTF device into one eye.

Sponsors & Collaborators

  • Neurotech Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Thomas Aaberg, Jr., MD · Neurotech Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-06
Primary Completion
2026-05-01
Completion
2026-07-24
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06397131 on ClinicalTrials.gov